The New York Genome Center said today that it plans to sequence 1,000 genomes from Alzheimer's patients over the next four years in order to better understand the genetic basis of the disease and the factors that contribute to disease risk and susceptibility.

The project is a collaboration between the NYGC, the Feinstein Institute for Medical Research, and Illumina, and will be the NYGC's first large-scale sequencing project.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.